|
Upcoming Events at the San Diego Chapter!
Chapter Homepage | Prior Events
San Diego Chapter Upcoming Event
The San Diego Chapter of the Licensing Executives Society invites you to join us for our upcoming March meeting.
TOPIC:
Big Pharma’s Perspective On Licensing Technology from Smaller Companies: Three Steps to A Deal Everyone Can Live With
FEATURED SPEAKER:
Richard B. Murphy, Director of Research Licensing for Schering-Plough Corporation
DATE:
Tuesday, March 15, 2005
TIME:
6:00 p.m. – Registration, Networking, Cocktails and Heavy Appetizers
7:00 p.m. – Presentation
LOCATION:
La Jolla Marriott
Salons F & G - Second Floor
4240 La Jolla Village Drive
San Diego , CA 92037
SUMMARY:
Mr. Murphy’s presentation will provide an overview from the perspective of a major pharmaceutical company working to establish a contractual relationship with a small biopharmaceutical company. The presentation will focus on the three main phases of the deal: preparation, negotiation, and “living with” the deal. In addition, Mr. Murphy will discuss:
- Legal due diligence leading up to the decision to enter into a strategic alliance;
- Difficult issues in the negotiation process and how they might be resolved; and
- Drafting considerations for unplanned occurrences.
The principles discussed here could be applied to many types of licensing situations.
Richard B. Murphy is Schering-Plough’s Director of Research Licensing for Schering-Plough Corporation where he is involved in the negotiation and drafting of a wide variety of contracts for Schering-Plough’s discovery, research and development operations. Mr. Murphy began his career at Schering-Plough as the Chief Counsel of Canji, Inc., a subsidiary focused on gene therapy and gene delivery technologies. In addition to his licensing responsibilities, he continues to oversee the gene delivery intellectual property for Schering-Plough. At Schering-Plough, he has been involved in major strategic alliances with Exelixis, Inc., LifeSpan, Transgene S.A., Immune Response Corporation, Targeted Genetics Corporation, Sennes Drug Innovations, Inc., BioVector Therapeutics, Inc., Insert Therapeutics, Inc. and Triad Therapeutics, Inc.
REGISTRATION:
$35 Members by March 9 th at 9:00 a.m.; $45 at the door (cash or check only)
$40 Non-Members by March 9 th at 9:00 a.m.; $50 at the door (cash or check only)
To reserve a guaranteed space, please register online using the links below with your credit card by March 9th, at 9:00 a.m. Seating is limited and will be on a first come, first served basis.
NOTE : This presentation will qualify for MCLE credit.
QUESTIONS:
Any questions or concerns may be directed to: mary.jo.farrell@saic.com
SPONSOR:
Burns Doane Swecker & Mathis L.L.P., has been in the business of representing technology companies for over 60 years. We are one of the few bi-coastal firms that specializes in intellectual property prosecution and transactions, with offices in Virginia , Redwood Shores and San Diego . Having a large percentage of Ph.D.s and former examiners in our ranks gives us the band width to provide an interdisciplinary, global, PTO-proactive approach to addressing complex intellectual property issues. Our local technical expertise spans the life sciences – drug discovery, molecular genetics, diagnostics, proteomics, medical devices, nanotechnology, plant genetics and vaccines. Additionally, we offer creative strategic approaches to addressing patent-related issues from inception to commercialization – we prepare and prosecute patent applications, defend them in appeals, oppositions and litigations, perform due diligence during financing transactions, prepare and negotiate technology license agreements, and have one of the nation's leading post-issuance practices specializing in interferences and reexaminations. For more information, contact Laurie Axford at 619-446-5622.
.
|
